ArticleJournal of thrombosis and thrombolysis2026
Long non-coding RNA NPPA-AS1 acts as a potential novel biomarker and promotes atrial fibrillation progression via the miR-302e/TGFBR2 axis.
Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) has complex etiologies. This study aimed to investigate the clinical significance of long non-coding RNA (lncRNA) NPPA-AS1 in AF and the pro-AF mechanism of the NPPA-AS1/miR-302e/transforming growth factor beta receptor 2 (TGFBR2) axis. This study included 120 patients with AF and 120 healthy controls. An in vitro AF model was established by stimulating rat primary cardiac fibroblasts (CFs) with angiotensin II (AngII). RT-qPCR, Cell Counting Kit-8 (CCK-8) assay, flow cytometry, and enzyme-linked immunosorbent assay (ELISA) were utilized to assess gene expression, cellular function, and protein concentration, respectively. Molecular target regulation relationships were validated using RNA immunoprecipitation (RIP) and dual luciferase assays. Target genes predicted by multiple databases were selected for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis to investigate the biological functions and related signaling pathways of the NPPA-AS1/miR-302e axis. NPPA-AS1 was highly expressed in AF patients, serving as an independent risk factor for AF onset while demonstrating excellent diagnostic efficacy for AF. Its expression may be closely associated with cardiac structural remodeling, myocardial injury, and inflammatory responses in AF patients. Mechanistically, NPPA-AS1 was found to act as a molecular sponge to negatively regulate miR-302e, which directly suppressed TGFBR2 expression, forming the NPPA-AS1/miR-302e/TGFBR2 regulatory axis. In vitro, this regulatory axis was associated with Ang II-induced cellular proliferation, apoptosis imbalance, expression of fibrotic molecules, and inflammatory factor secretion (tumor necrosis factor alpha [TNF-α], interleukin 6 [IL-6]), suggesting a potential role in AF-related pathological processes. Specifically, interference with NPPA-AS1 reversed these pathological effects, while inhibition of miR-302e counteracted this reversal. Further interference with TGFBR2 could re-block the pathological process. In vitro findings suggest that NPPA-AS1 may amplify AngⅡ-induced atrial fibrosis and inflammation by releasing TGFBR2 inhibition through "sponge-like" adsorption of miR-302e, indicating a potential contributory role in AF pathogenesis.
Indexed as
Identifiers
42268505What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.